

Supplemental Information

Chemo-Selective Syntheses of N-*t*-*bo*c-Protected Amino Ester Analogs Through Buchwald Hartwig Amination

Sujit Suwal*, Mahmuda Rahman, Gregory O'Brien, Victoire G. Karambizi, Matthew Wrotny, M. Scott Goodman

Contents:

S. No.	Title	Page #
1	Chemical and Solvents	S2
2	Instruments	S2
3	General Synthesis Protocol	S2
4	Scheme 1	S3
5	Table 1	S3
6	Table 2	S4
	Spectral Analysis	
8	Compound 3	S5
9	Compound 1.5	S7
10	Compound 8.5	S9
11	Compound 9.5	S12
12	Compound 10.5	S14
13	Compound 11.5	S17
14	Compound 1.6	S19
15	Compound 8.6	S22
16	Compound 9.6	S24
17	Compound 10.6	S27
18	Compound 11.6	S30
19	Compound 1.7	S32
20	Compound 9.7	S34
21	Compound 10.7	S36
22	Compound 11.7	S38
23	Compound 12.5	S40
24	Compound 13.5	S43
25	Compound 12.6	S45
26	Compound 13.6	S47
27	Compound 12.7	S50
28	Compound 13.7	S52
29	Compound 14.5	S54
30	Compound 14.6	S56
31	Compound 14.7	S58

1. Chemicals and solvents:

Cesium carbonate and Ethyl-2-Chloropyrimidine-5-carboxylate was purchased from Alpha Aesar. PEPPSI-IPr Catalyst, Methyl-6-chloronicotinate, Methyl-6-Bromonicotinate, Methyl-2-chlorobenzoate from Sigma-Aldrich. Methyl-2-bromobenzoate, Ethyl-4-bromobenzoate was bought from Acros Organics. Likewise, Methyl-6-Bromonicotinate, methyl-5-bromonicotinate, methyl-2-bromonicotinate, 6-chloronicotinate, ethyl-2-bromothiazole-4-carboxylate, Methyl-2-chlorothiazole-4-carboxylate, Ethyl-2-chloropyrimidine-5-carboxylate, Methyl-3-bromo pyrimidine-2-carboxylate, Methyl-5-chloropyrazine-2-carboxylate, Methyl-6-chloropyrazine-2-carboxylate, methyl-3-chloropyrazine-2carboxylate, Methyl-3-bromopyrazine-2-carboxylate, and Methyl-2-Chloronicotinate were purchased from Combi-block. Sodium Sulfate and n-Hexanes were purchased from JT-Baker. We used Dichloromethane and Ethyl Acetate obtained from Macron. 1-Boc Piperazine, (S)-2-MethylPiperazine, (3S)-(-)-3-(t-butoxycarbonyl amino) Pyrrolidine were obtained from Oakwood Chemicals. Silica Gel (200-400 mesh) were purchased from Silica-Flash. Di-methoxy-ethane, Ethyl-2-bromobenzoate, Ethyl-3-bromobenzoate were bought from TCI.

2. Instruments:

^1H and ^{13}C NMR spectra were recorded in Bruker 400 instrument operating at 400 MHz for ^1H and 100 MHz for ^{13}C NMR using Deuterated-chloroform (CDCl_3) or Deuterated-Dimethylsulfoxide ($\text{D}_6\text{-DMSO}$) (Cambridge) as a solvent. Chemical shifts δ are reported in ppm, multiplicity is reported as follows: s = singlet, d = doublet, t = triplet, q = quartet, quint. = quintet, sext. = sextet, sept. = septet, m = multiplet or unresolved and coupling constant J in Hz. For LCMS, we used Ultimate3000-ThermoExactive. IR spectra were recorded in Nicolet iS50 FT-IR. The absorption is reported in cm^{-1} and the IR bands were assigned as s (strong), m (medium) or w (weak).

3. General Synthesis Protocol:

Method 1:


A halo-ester (1x) in a round bottomed flask purged with argon was dissolved with DME under the anhydrous condition. Roughly 3 mol% of Pd-catalyst was added followed by secondary amine (2x) and cesium carbonate (2x). The reaction was heated to 60–80°C in the oil bath. The progress of reaction was monitored by TLC. For heterocyclic ester, the reactions were found to complete within 3-4 hr. Once the reaction was completed, ethyl acetate was added, stirred, and filtered. Residue was washed with excess amount to ethyl acetate. The crude compound was concentrated and purified using flash chromatography through silica using hexane and ethyl acetate solution in a different ratio.

Method 2:

For alkyl halobenzoates, all the experimental precursors and reagents were kept identical except 7 mol% of Pd-catalyst was used and the reaction was incubated overnight up to 120°C.

Scheme 1:

(I) A scheme of chemo-selective BHA cross-coupling between heterocyclic halo-esters and secondary amine.



(II) A general scheme showing for chemo-selective BHA cross-coupling between aryl/heterocyclic halo-esters and *N*-*t*-boc diamine.




Table 1: A list of BHA products and their yield resulted by reacting different haloesters (left column) and the *N*-*t*-boc diamines (top row)









































			
	 1.5 yield = 95%	 1.6 yield = 90%	 1.7 yield = 91%
	 8.5 yield = 82%	 8.6 yield = 65%	N.R.
	 9.5 yield = 94%	 9.6 yield = 89%	 9.7 yield = 88%
	 10.5 yield = 95%	 10.6 yield = 91%	 10.7 yield = 76%
	 11.5 yield = 79%	 11.6 yield = 74%	 11.7 yield = 72%

Table 2: A list of BHA products and their yield resulted by reacting different haloesters (left column) and the N-tboc diamines (toprow)



	 5	 6	 7
 12	 12.5 yield = 84%	 12.6 yield = 76%	 12.7 yield = 80%
 13	 13.5 yield = 82%	 13.6 yield = 77%	 13.7 yield = 75%
 14	 14.5 yield = 77%	 14.6 yield = 73%	 14.7 yield = 72%
 15	N.R.	N.R.	N.R.
 16	N.R.	N.R.	N.R.



Spectral Analysis:


Spectral data of Compound 3



IR (cm⁻¹): 2939(w), 2853(w), 1704(s), 1600(s), 1434(m), 1244 (m), 1219 (m), 1115(m); ¹HNMR (400 MHz) δ: 8.78 (dd, *J*=2.4, 0.7, 1H), 7.97(dd, *J*=9.0, 2.4, 1H), 6.58-6.56 (dd, *J*=9.0, 0.7, 1H) 3.86 (s, 3H), 3.6-3.68 (m, 4H), 1.70–1.61 (m, 6H); ¹³CNMR (100 MHz): 166.6, 160.6, 151.3, 138.3, 113.4, 104.9, 51.5, 45.8, 25.6, 24.7; ESI-MS: Observed MH⁺ = 221.1303 (Expected MH⁺ = 221.1212)







:Nico-piperidine #98-192 RT: 0.33-0.65 AV: 95 SB: 45 0.24-0.39 NL: 1.05E8
 : FTMS (1.1) + p ESI Full ms [125.00-2500.00]








Fig S1: Figure representing IR, ¹H-NMR, ¹³C-NMR, DEPT, COSY, ESI-MS of compound 3


Spectral data of compound 1.5



IR (cm⁻¹): 2974 (w), 1706 (m), 1670(m), 1603 (m), 1392 (m), 1281(s), 1163 (s), 1080 (s), 770 (s), NMR (400 MHz, CDCl₃, [ppm]) δ: 8.81 (dd, *J*=2.4, 0.7, 1H), 8.05(dd, *J*=9.0, 2.4, 1H), 6.6 (dd, *J*=9.0, 0.7, 1H), 3.89(s,

3H), 3.70(m, 4H), 3.56(m, 4H), 1.50(t, 9H); CNMR (100 MHz, CDCl₃, [ppm]): 166.6, 160.6, 154.8, 151.0, 138.3, 115.1, 105.2, 80.2, 51.7, 44.4, 20.42; ESI-MS: MH⁺ = 322.1757 (expected MH⁺ = 322.1689)





Nico-pip-tboc #219-361 RT: 2.04-3.23 AV: 143 NL: 8.48E6
 : FTMS {1.1} + p ESI Full ms2 1000.00@hcd10.00 [100.00-500.00]







Fig S2: Figure representing IR, ¹H-NMR, ¹³C-NMR, DEPT, ESI-MS of compound 1.5



Spectral data of Compound 8.5



IR (cm⁻¹): 2977(s), 1690 (s), 1610 (m), 1519 (s), 1288 (m), 1238 (m), 1160 (m), 1118 (m), 769 (s); NMR (400MHz, CDCl₃, [ppm]) δ: 7.96 (d, *J*=8.9 Hz, 2H), 6.88(d, *J*=8.9 Hz, 2H), 4.35 (q, *J*=7.1 Hz, 2H), 3.59(m, *J*=4.9Hz, 4H), 3.30(m, *J*=4.9Hz, 4H), 1.50(s, 9H), 1.38(t, *J*=7.1Hz, 3H); CNMR (100 MHz, CDCl₃, [ppm]): 166.5,

154.6, 153.9, 131.2, 120.6, 114.0, 80.1, 60.4, 47.6, 28.4, 14.4; ESI-MS: MH+ = 335.1962 (expected MH+ = 335.1893)





AAS-1 #1391-1461 RT: 4.70-4.94 AV: 71 NL: 8.06E7
T: FTMS [1,1] + p ESI Full ms [125.00-2500.00]








Fig S3: Figure representing IR, ¹H-NMR, ¹³C-NMR, DEPT, ESI-MS of compound 8.5


Spectral data of 9.5



IR (cm⁻¹): 2985(w), 1728(m), 1693 (s), 1420 (m), 1382 (s), 1238 (s), 1157 (m), 1140 (s); NMR (400 MHz, CDCl₃, [ppm]) δ: 8.82 (d, *J*=1.3 Hz, 1H), 8.15(d, *J*=1.3 Hz, 1H), 3.97 (s, 3H), 3.77 – 3.75(m, 4H), 3.60(m, 4H), 1.50(s, 9H); CNMR (100 MHz, CDCl₃, [ppm]): 165.1.5, 155.0, 154.6, 145.3, 131.3, 129.3, 80.4, 52.3, 43.9, 28.4; ESI-MS: MH⁺ = 323.1707 (expected MH⁺ = 323.1641)







AAS-7 #1207-1346 RT: 4.08-4.55 AV: 140 NL: 4.90E7
 T: FTMS (1,1) + p ESI Full ms [125.00-2500.00]







Fig S4: Figure representing IR, ¹H-NMR, ¹³C-NMR, DEPT, ESI-MS of compound 9.5


Spectral data of 10.5



IR (cm⁻¹): 2978 (w), 1698 (s), 1677 (s), 1601 (s), 1530 (s), 1310 (s), 1248 (s), 1100(s); NMR (400 MHz, CDCl₃, [ppm]) δ: 8.86 (s, 2H), 4.38-4.33 (q, *J*=7.1, 2H), 3.94-3.91 (m, 4H), 3.53-3.5 (m, 4H), 1.50 (s, 9H), 1.38 (t,

$J=7.1, 3\text{H}$); CNMR (100 MHz, CDCl_3 , [ppm]): 164.7, 162.3, 159.8, 154.7, 113.0, 80.2, 60.6, 43.7, 28.4; 14.3; ESI-MS: $\text{MH}^+ = 337.1798$ (expected $\text{MH}^+ = 337.1798$)





AAS-10 #1382-1521 RT: 4.67-5.14 AV: 140 NL: 2.53E7
T: FTMS [1.1] + p ESI Full ms [125.00-2500.00]








Fig S5: Figure representing IR, ¹H-NMR, ¹³C-NMR, DEPT, ESI-MS of compound 10.5

Spectral data of 11.5



IR (cm⁻¹): 3145 (w), 2979 (w), 2829 (w), 1700 (m), 1690 (s), 1519 (m), 1417 (m), 1219 (s), 1197 (s), 1130 (s), 1080 (m); NMR (400 MHz, CDCl₃, [ppm]) δ: 7.46 (s, 1H), 4.35 (q, *J*=7.0 Hz, 2H), 3.52 (m, 8H), 1.47 (s, 9H), 1.36 (t, *J*=7.0 Hz, 3H); CNMR (100 MHz, CDCl₃, [ppm]): 170.8, 161.6, 154.5, 144.0, 116.7, 80.3, 61.1, 48.3, 28.4; 14.3; ESI-MS: MH⁺ = 342.1474 (expected MH⁺ = 342.1409)












Fig S6: Figure representing IR, $^1\text{H-NMR}$, $^{13}\text{C-NMR}$, DEPT, ESI-MS of compound 11.

Spectral Data 1.6



IR (cm^{-1}): 2973 (w), 1720 (w), 1686 (s), 1556 (w), 1438 (w), 1402 (w), 1159 (s), 1100 (s); NMR (400 MHz, CDCl_3 , [ppm]) δ : 8.79 (dd, 1H), 8.03 (dd, 1H), 6.55 (dd, 1H), 4.35 (bs, 1H), 4.23-4.20 (dm, 1H), 4.15-4.10 (dq, 1H), 3.97-3.92 (dt, 1H), 3.88 (s, 3H), 3.44-3.39 (dd, 1H), 3.31-3.24 (m, 1H), 3.17-3.09 (td, 1H), 1.50 (s, 9H),










Fig S7: Figure representing IR, ¹H-NMR, ¹³C-NMR, DEPT, ESI-MS of compound 1.6


Spectral data of 8.6



IR (cm⁻¹): 2974 (w), 1706 (m), 1670 (m), 1603(m), 1392 (m), 1281 (m), 1220 (m), 1100 (s); NMR (400 MHz, CDCl₃, [ppm]) δ: 7.90 (d, 2H), 6.79 (d, 2H), 4.32(m, 1H), 3.94-3.89 (td, 1H), 3.84 (s, 3H), 3.66-3.63 (dm, 1H), 3.55-3.51 (dm, 1H), 3.31-3.25 (m, 1H), 3.16-3.12 (dd, 1H), 2.97-2.91 (td, 1H), 1.47(s, 9H), 1.23 (d, 3H); CNMR (100 MHz, CDCl₃, [ppm]): 166.4, 160.8, 154.7, 151.1, 138.6, 114.7.3, 104.6, 80.0, 51.6, 47.9, 44.5, 28.4; 16.3; ESI-MS: MH⁺ = 335.1963 (expected MH⁺ = 335.1893)







AAS-2 #1391-1438 RT: 4.70-4.86 AV: 48 NL: 4.32E7
 T: FTMS (1,1) + p ESI Full ms [125.00-2500.00]







Fig S8: Figure representing IR, ¹H-NMR, ¹³C-NMR, DEPT, ESI-MS of compound 8.6

Spectral Data of 9.6



IR (cm⁻¹): 2981 (w), 1728 (s), 1694 (m), 1676(m), 1522 (m), 1470 (s), 1410 (s), 1270 (s), 1160 (s), 1080 (s);
 NMR (400 MHz, CDCl₃, [ppm]) δ: 8.79 (d, *J*=1.3, 1H), 8.10 (d, *J*=1.3, 1H), 4.37 (bs, 1H), 4.29-4.26 (d, *J*=11.7, 1H), 4.18 – 4.14 (m, 1H), 4.0 (m, 1H), 3.96 (s, 3H), 3.47 – 3.42 (dd, *J*=4.1, 13.4, 1H), 3.31 – 3.16 (m, 2H),



AAS-8 #1257-1400 RT: 4.25-4.73 AV: 144 NL: 4.75E7
T: FTMS (1,1) + p ESI Full ms [125.00-2500.00]








Fig S9: Figure representing IR, ¹H-NMR, ¹³C-NMR, DEPT, ESI-MS of compound 9.6


Spectral data of 10.6



IR (cm⁻¹): 2981 (w), 1728 (s), 1694 (s), 1676 (s), 1552 (m), 1410 (s), 1225 (s), 1123 (m), 1075 (s); NMR (400 MHz, CDCl₃, [ppm]) δ: 8.85 (d, 2H), 4.73 – 4.69 (bd, 1H), 4.65 – 4.61 (dt, 1H), 4.33-4.38 (m, 3H), 3.95 (bd, 1H), 3.31-3.27 (dd, *J*=3.9, 13.4, 1H), 3.21 – 3.08 (m, 2H), 1.50 (s, 9H), 1.38 (t, *J*=7.15, 3H), 1.13 (d, *J*= 6.7, 3H), CNMR (100 MHz, CDCl₃, [ppm]): 164.8, 162.9, 159.8, 154.6, 112.8, 80.0, 60.8, 47.6, 47.5, 43.8, 38.4; 28.4, 15.5, 14.3; ESI-MS: MH⁺ = 350.2024 (expected MH⁺ = 350.1954)







AAS-11 #1412-1503 RT: 4.77-5.08 AV: 92 NL: 8.51E7
 T: FTMS (1,1) + p ESI Full ms [125.00-2500.00]







Fig S10: Figure representing IR, ¹H-NMR, ¹³C-NMR, DEPT, COSY, ESI-MS of compound 10.6

Spectral Data 11.6



IR (cm⁻¹): 3145 (w), 2979 (w), 2829 (w), 1700 (m), 1690 (s), 1519 (m), 1417 (m), 1219 (s), 1197 (s), 1130 (s), 1080 (m); NMR (400 MHz, DMSO-D₆, [ppm]) δ : 7.71 (s, 1H), 4.21-4.26 (m, 3H), 3.84-3.80 (m, $J=7.1$, 2H), 3.69-3.65 (m, 1H), 3.28-3.2 (dd, $J=4.0, 13.0$, 1H), 3.20-3.13 (m, 1H), 3.07 - 3.00 (td, $J=3.5, 11.7$, 1H), 1.42 (s, 9H); 1.27 (t, $J=7.1$, 3H), 1.12 (d, $J=6.7$, 3H); CNMR (100 MHz, DMSO-D₆, [ppm]): 171.2, 161.4, 154.2, 143.3, 118.2, 79.7, 60.8, 52.4, 48.0, 46.8, 38.1, 28.5, 15.9, 14.7; ESI-MS: MH⁺ = 356.1631 (expected MH⁺ = 356.1566)











Fig S11: Figure representing IR, ¹H-NMR, ¹³C-NMR, DEPT, ESI-MS of compound 11.6

Spectral data of 1.7



IR (cm⁻¹): 3386 (w), 2970 (w), 1698(s), 1523 (m) 1466(s), 1446(s), 1367(m), 1160(s), 1120(s); NMR (400 MHz, CDCl₃, [ppm]) δ: 8.80 (d, *J*=2.2, 1H), 8.03-8.00 (dd, *J*=2.2, 8.8, 1H), 6.33-6.35 (d, *J*=8.8, 1H), 4.76 (bs, 1H), 4.37 (bs, 1H), 3.88 (s, 3H), 3.83-3.78 (dd, 1H), 3.66-3.62 (m, 2H), 3.43-3.40 (m, 1H), 2.35-2.26 (sext, *J*=6.6, 1H), 2.05-1.97 (sext, *J*=6.6, 1H), 1.47 (s, 9H); CNMR (100 MHz, CDCl₃, [ppm]): 166.7, 158.8, 155.3, 151.4, 138.1, 114.1, 105.4, 52.8, 51.6, 44.9, 31.6, 28.4; ESI-MS: MH⁺ = 322.1762 (expected MH⁺ = 322.1689)













Fig S12: Figure representing IR, ¹H-NMR, ¹³C-NMR, DEPT, ESI-MS of compound 1.7

Spectral data of 9.7



IR (cm⁻¹): 3375(w), 3331(w), 2980(s), 2872(w), 1710(s), 1698(s), 1582(w), 1521 (m), 1283(m), 1164 (m), 1138(m), 1011(m) ; NMR (400 MHz, CDCl₃, [ppm]) δ: 8.79 (d, *J*=2.5, 1H), 7.88 (d, *J*=2.5, 1H), 4.83 (bs, 1H), 4.38 (bs, 1H), 3.94 (s, 3H), 3.87-3.82 (dd, *J*=6.2, 1H), 3.74-3.64 (m, 2H), 3.49-3.46 (dd, *J*=6.2, 1H), 2.37-2.28 (sext, *J*=6.6, 1H), 2.06-2.01 (sext, *J*=6.6, 1H), 1.44 (s, 9H); CNMR (100 MHz, CDCl₃, [ppm]): 165.4, 155.3, 153.4, 145.8, 130.6, 129.6, 80.1, 52.5, 52.2, 44.9, 31.4, 28.3; ESI-MS: Observed MH⁺ = 323.1709 (Expected MH⁺ = 323.1641)












Fig S13: Figure representing IR, ¹H-NMR, ¹³C-NMR, DEPT, ESI-MS of compound 9.7


Spectral Data of 10.7



IR (cm⁻¹): 3375(w), 3331(w), 2980(s), 2872(w), 1710(s), 1698(s), 1582(w), 1521 (m), 1283(m), 1164 (m), 1138(m), 1011(m); NMR (400 MHz, CDCl₃, [ppm]) δ: 8.87 (s, 2H), 4.72 (s, 1H), 4.38-4.33 (m, 3H), 3.95-3.91 (dd, *J*=4.3, 12.2, 1H), 3.80-3.68 (m, 2H), 3.56-3.52 (dd, *J*=4.5, 12.2, 1H), 2.35-2.26 (m, 1H), 2.04–1.96 (sext, *J*=6.1, 1H), 1.47 (s, 9H), 1.40-1.37 (t, *J*=7.1, 3H); CNMR (100 MHz, CDCl₃, [ppm]): 165.0, 160.9, 159.7, 155.2, 112.7, 60.6, 52.8, 44.9, 31.6, 28.3, 14.3; ESI-MS: MH⁺ = 337.1870 (expected MH⁺ = 337.1798)







AAS-12 #1237-1391 RT: 4.18-4.70 AV: 155 NL: 6.52E7
 T: FTMS (1.1) + p ESI Full ms [125.00-2500.00]








Fig S14: Figure representing IR, ¹H-NMR, ¹³C-NMR, DEPT, ESI-MS of compound 10.7

Spectral data of 11.7



IR (cm⁻¹): 3280(w), 3130(w), 2974(w), 2930(w), 1701(s), 1550(s), 1534(s), 1329(m), 1240(s), 1153(s), 1088(m); NMR (400 MHz, DMSO-D₆, [ppm]) δ: 7.59 (s, 1H), 7.27 (bd, 1H), 4.26-4.21 (q, *J*=7.1, 2H), 4.17-4.11 (m, 1H), 3.62-3.58 (dd, *J*=6.2, 1H), 3.54-3.48 (m, 1H), 3.42-3.36 (m, 1H), 3.25-3.22 (dd, *J*=4.5, 10.3, 1H), 2.22-2.14 (m, 1H), 1.96-1.88 (m, 1H), 1.40 (s, 9H), 1.27-1.25 (t, *J*= 7.1, 3H); CNMR (100 MHz, DMSO-D₆, [ppm]): 166.9, 161.6, 155.7, 143.8, 117.1, 78.4, 60.7, 55.4, 50.6, 48.2, 31.3, 28.6, 14.7; ESI-MS: MH⁺ = 342.1477 (expected MH⁺ = 342.1409)













Fig S15: Figure representing IR, ¹H-NMR, ¹³C-NMR, DEPT, ESI-MS of compound 11.7

Spectral data of 12.5



IR (cm⁻¹): 2974(w), 2864(w), 1711(m), 1681 (s), 1583(m), 1551(m), 1439(m), 1200(s), 1120(s), 1086(s);
NMR (400 MHz, DMSO-D₆, [ppm]) δ: 8.31-8.29 (dd, *J*=4.6, 1.9, 1H), 7.97-7.95 (dd, *J*=1.9, 7.6, 1H), 6.89-6.86 (dd, *J*=4.6, 7.6, 1H), 3.83 (s, 3H), 3.44-3.41 (m, 4H), 3.30-3.28 (m, 4H), 1.42 (s, 9H); CNMR (100 MHz, DMSO-D₆, [ppm]): 167.5, 159.3, 154.9, 150.6, 140.9, 114.5, 113.8, 79.8, 52.1, 49.1, 28.4; ESI-MS: MH⁺ = 322.1753 (Expected MH⁺ = 322.1689)





AAS-16 #1219-1400 RT: 4.12-4.73 AV: 182 NL: 8.61E7
T: FTMS {1,1} + p ESI Full ms [90.00-1800.00]









Fig S16: Figure representing IR, ¹H-NMR, ¹³C-NMR, DEPT, COSY ESI-MS of compound 12.5

Spectral data of 13.5



IR (cm⁻¹): 2978(w), 2863(w), 1710(m), 1682(s), 1556(w), 1399(m), 1242(m), 1144(m), 1110(s); NMR (400 MHz, CDCl₃, [ppm]) δ: 8.21 (d, *J*=2.3Hz, 1H), 8.03 (d, *J*=2.3Hz, 1H), 3.99 (s, 3H), 3.58-3.56(m, 4H), 3.49 - 3.47(m, 4H), 1.49 (s, 9H); CNMR (100 MHz, CDCl₃, [ppm]): 166.2, 154.7, 154.6, 143.6, 133.5, 130.8, 80.1, 52.9, 47.9, 28.4; ESI-MS: MH⁺ = 323.1708 (Expected MH⁺ = 323.1641)





AAS-22 #1192-1287 RT: 4.03-4.35 AV: 96 NL: 5.78E7
T: FTMS [1,1] + p ESI Full ms [90.00-1800.00]









Fig S17: Figure representing IR, ¹H-NMR, ¹³C-NMR, DEPT, ESI-MS of compound 13.5

Spectral data of 12.6



IR (cm⁻¹): 2974(w), 1690(w), 1574(m), 1565(m), 1556(w), 1351(m), 1242(m), 1160(s), 1081(s); NMR (400 MHz, CDCl₃, [ppm]) δ: 8.28-8.26 (dd, *J*=4.6, 1.9, 1H), 7.98-7.96 (dd, *J*=1.9, 7.6, 1H), 6.77-6.73 (dd, *J*=4.6, 7.6, 1H), 4.28 (bs, 1H), 3.89 (s, 3H), 3.86-3.81 (dt, *J*=3.1, 13.14, 1H), 3.70-3.68 (m, 2H), 3.40-3.27 (m, 2H), 3.04-2.97 (m, 1H), 1.48 (s, 9H), 1.20 (d, *J*=6.5 Hz, 3H); CNMR (100 MHz, CDCl₃, [ppm]) δ: 167.7, 159.7, 154.8, 150.5, 140.7, 114.0, 113.6, 79.7, 52.2, 52.0, 49.7, 28.5, 16.28; ESI-MS: Observed Mass MH⁺: 336.1914 (Exact Mass MH⁺: 336.1845)












Fig S18: Figure representing IR, $^1\text{H-NMR}$, $^{13}\text{C-NMR}$, DEPT, COSY, ESI-MS of compound 12.5

Spectral data of 13.6





AAS-23 #1246-1459 RT: 4.21-4.93 AV: 214 NL: 6.85E7
 T: FTMS (1,1) + p ESI Full ms [90.00-1800.00]






Fig S19: Figure representing IR, ¹H-NMR, ¹³C-NMR, DEPT, ESI-MS of compound 13.5



AAS-18 #756-1323 RT: 2.56-4.47 AV: 568 NL: 1.82E7
T: FTMS (1.1) + p ESI Full ms [90.00-1800.00]








Fig S20: Figure representing IR, ¹H-NMR, ¹³C-NMR, DEPT, ESI-MS of compound 12.7


Spectral data of 13.7



IR (cm⁻¹): 3386(w), 2973(w), 1694(s), 1557(w), 1497(m), 1462(m), 1294(m), 1282(m), 1173(m), 1110(s);
NMR (400MHz, DMSO-D₆, [ppm]) δ: 8.25-8.24 (d, *J*=1.9Hz, 4.7Hz, 1H), 7.88-7.87 (d, *J*=1.9Hz, 7.6Hz, 1H),
7.18 (d, 1H), 4.05 (bm, 1H), 3.87 (s, 3H), 3.50 – 3.46 (dd, *J*=5.3 Hz, 10.7 Hz, 1H), 3.50-1.99 (m, 2H), (dd,
J=4.6, 11.2, 1H), 2.12-2.04 (m, 1H), 1.90-1.83 (m, 1H), 1.38 (s, 9H); CNMR (100 MHz, DMSO-D₆, [ppm]):
167.0151.0, 144.2, 130.9, 129.8, 78.3, 54.1, 52.9, 50.2, 46.9, 30.7, 28.7; ESI-MS: MH⁺ = 323.1714 (Expected
MH⁺ = 323.1641)







AAS-24 #997-1361 RT: 3.37-4.60 AV: 365 NL: 1.78E7
 T: FTMS (1,1) + p ESI Full ms [90.00-1800.00]








Fig S21: Figure representing IR, ¹H-NMR, ¹³C-NMR, DEPT, ESI-MS of compound 13.7

Spectral data of 14.5



IR (cm⁻¹): 2973(w), 2929(w), 1736(m), 1679 (s), 1577 (w), 1526(w), 1422(m), 1232w (s), 1135 (s), 1140 (s); NMR (400 MHz, CDCl₃, [ppm]) δ: 8.57 (bs, 1H), 8.15(bd, 1H), 3.98 (s, 3H), 3.71-3.68 (m, 4H), 3.60-3.58 (m, 4H), 1.50 (s, 9H); CNMR (100 MHz, CDCl₃, [ppm]) δ: 165.2, 154.6, 153.9, 140.2, 134.2, 133.9, 80.3, 52.6, 44.2, 28.4; ESI-MS: MH⁺ = 323.1717 (expected MH⁺ = 323.1641)








Fig S22: Figure representing IR, ¹H-NMR, ¹³C-NMR, DEPT, ESI-MS of compound 14.5

Spectral data of 14.6



IR (cm⁻¹): 2977(w), 2877(w), 1748(m), 1686(s), 1573(m), 1393(m), 1364(m), 1289(m), 1150(s), 1025(s);
NMR (400 MHz, CDCl₃, [ppm]) δ: 8.54 (s, 1H), 8.27 (s, 1H), 4.38 (bm, 1H), 4.29 – 4.25 (bd, 1H), 4.09 – 4.05 (m, 1H), 4.01-3.99 (m, 1H), 3.97 (s, 3H), 3.42 – 3.37(dd, *J*=4.0, 13.1, 1H), 3.32 – 3.25(m, 1H), 3.16 – 3.09 (dt, *J*=3.85, 12.1, 1H), 1.50 (s, 9H), 1.22-1.20 (d, *J*=6.6, 3H); CNMR (100 MHz, CDCl₃, [ppm]) δ: 165.2, 154.6, 154.2, 140.2, 133.8, 133.6, 80.1, 52.6, 47.9, 44.2, 28.4, 16.2; ESI-MS: MH⁺ = 337.1857 (Expected MH⁺ = 337.1798)








Fig S23: Figure representing IR, ¹H-NMR, ¹³C-NMR, DEPT, ESI-MS of compound 14.6

Spectral data of 14.7



IR (cm⁻¹): 3354(m), 2976(w), 2876(w), 1719(s), 1676(s), 1504(s), 1480(w), 1445(w), 1339(m), 1288(w), 1159(s), 1016(s); NMR (400 MHz, DMSO-D₆, [ppm]) δ: 8.33 (s, 1H), 8.16 (s, 1H), 7.23 (d, 1H), 4.14 (bm, 1H), 3.87 (s, 3H), 3.70 – 3.66 (dd, *J*=6.1, 11, 1H), 3.62 – 3.56 (m, 1H), 3.52 – 3.46 (m, 1H), 3.34-3.30 (dd, *J*=6.1, 11, 1H), 2.19-2.11 (sext, *J*=6.2, 1H), 1.96-1.88 (m, *J*=7.1, 1H), 1.40 (s, 9H); CNMR (100 MHz, DMSO-D₆, [ppm]) δ: 165.5, 155.7, 152.4, 140.5, 135.0, 132.0, 78.4, 52.8, 52.4, 50.2, 45.0, 30.9, 28.9; ESI-MS: MH⁺ = 323.1718 (Expected MH⁺ = 323.1641)









Fig S24: Figure representing IR, $^1\text{H-NMR}$, $^{13}\text{C-NMR}$, DEPT, ESI-MS of compound 14.7